Toppila, Iiro
Kysenius, Kai
Miettinen, Tatu
Lassenius, Mariann Ida
Lievonen, Juha
Anttila, Pekka
Funding for this research was provided by:
Takeda Pharmaceuticals International
Article History
Received: 7 April 2022
Accepted: 14 August 2022
First Online: 13 September 2022
Declarations
:
: The study was approved by each registered holder.
: KK, IT, MIL, and TM are employees of Medaffcon Oy; TM is an employee of Takeda Finland; JL has received consultation fees from Amgen, Celgene, Bristol-Myers Squibb, Sanofi, Takeda, Janssen, and travel grants from Janssen, Celgene, Amgen, Novartis, TEVA, Takeda, Roche, Abbvie, Pfizer; PA has been the Hematologist in charge for treatment of plasma cell malignancies at the Helsinki University Hospital and has received consultation fees from Amgen, BMS, Celgene, GSK, Janssen, Novartis, Sanofi and Takeda, and travel grants from AbbVie, Amgen, BMS, Celgene, Sanofi Genzyme, Janssen, Mundipharma, Novartis, Roche, and Teva.